# Metamark Genetics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/metamark-genetics

- Industry: Biotechnology
- Headquarters: Norfolk, US
- Website: www.metamarkgenetics.com
- Total disclosed funding: $22M
- Latest round: Series B (Aug 13, 2010)
- Investors on record: 1

## About

Metamark Genetics Inc. is a biotechnology company focused on innovative genetic testing solutions that aim to enhance patient care and improve clinical outcomes through advanced diagnostic capabilities.Founded in 2007 in Norfolk, US, Metamark Genetics Inc. specializes in genetic testing and diagnostics. The company has engaged in three investment deals, with the most recent funding round being a Series B round that raised USD 13 mn on November 5, 2012. The current company valuation is USD 214.625 mn.Metamark Genetics Inc. provides advanced genetic testing services aimed at improving patient care. Their offerings include diagnostic tests that utilize cutting-edge technology to analyze genetic information, assisting healthcare providers in making informed clinical decisions. The company’s solutions are designed to cater to various medical fields, enhancing the capabilities of healthcare professionals in understanding genetic predispositions and treatment responses.The revenue model at Metamark Genetics Inc. is based on direct sales of genetic testing services and subscription agreements for ongoing diagnostic support. Clients typically engage in annual contracts that ensure access to the latest testing capabilities and customer service. The firm also collaborates with healthcare providers to streamline access to its services, reinforcing a sustainable revenue stream through long-term relationships.Metamark Genetics Inc. plans to enhance its product line with the introduction of new genetic tests targeting specific diseases and conditions, expected to launch in the coming years. The company aims to expand its market presence in North America and Europe, with a focused effort on reaching new healthcare providers and institutions by 2025. The funds raised in the Series B financing will support these initiatives, enabling the development of advanced testing solutions and facilitating market entry into new regions.

## Funding rounds

- Series B, Aug 13, 2010, $22M — Perseus

## Investors

- Perseus (https://capitalatlas.ai/funds/perseus) — Series B